98 related articles for article (PubMed ID: 10882583)
21. The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages.
Kedzierska K; Crowe SM; Turville S; Cunningham AL
Rev Med Virol; 2003; 13(1):39-56. PubMed ID: 12516061
[TBL] [Abstract][Full Text] [Related]
22. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
[TBL] [Abstract][Full Text] [Related]
23. Soluble CD40 ligand induces beta-chemokine production by macrophages and resistance to HIV-1 entry.
di Marzio P; Mariani R; Lui R; Thomas EK; Landau NR
Cytokine; 2000 Oct; 12(10):1489-95. PubMed ID: 11023663
[TBL] [Abstract][Full Text] [Related]
24. [Role of chemokines in the HIV infection process].
Proost P; Schols D
Verh K Acad Geneeskd Belg; 2002; 64(6):403-20. PubMed ID: 12649932
[TBL] [Abstract][Full Text] [Related]
25. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
[TBL] [Abstract][Full Text] [Related]
26. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
27. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step.
Barbouche R; Decroly E; Kieny MP; Fenouillet E
Virology; 2000 Jul; 273(1):169-77. PubMed ID: 10891419
[TBL] [Abstract][Full Text] [Related]
28. Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages.
Ylisastigui L; Vizzavona J; Drakopoulou E; Paindavoine P; Calvo CF; Parmentier M; Gluckman JC; Vita C; Benjouad A
AIDS; 1998 Jun; 12(9):977-84. PubMed ID: 9662193
[TBL] [Abstract][Full Text] [Related]
29. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.
Alkhatib G; Combadiere C; Broder CC; Feng Y; Kennedy PE; Murphy PM; Berger EA
Science; 1996 Jun; 272(5270):1955-8. PubMed ID: 8658171
[TBL] [Abstract][Full Text] [Related]
30. Induction of rapid and extensive beta-chemokine synthesis in macrophages by human immunodeficiency virus type 1 and gp120, independently of their coreceptor phenotype.
Choe W; Volsky DJ; Potash MJ
J Virol; 2001 Nov; 75(22):10738-45. PubMed ID: 11602715
[TBL] [Abstract][Full Text] [Related]
31. The inhibitory effect of RANTES on the infection of primary macrophages by R5 human immunodeficiency virus type-1 depends on the macrophage activation state.
Amzazi S; Ylisastigui L; Bakri Y; Rabehi L; Gattegno L; Parmentier M; Gluckman JC; Benjouad A
Virology; 1998 Dec; 252(1):96-105. PubMed ID: 9875320
[TBL] [Abstract][Full Text] [Related]
32. Effect of RANTES on the infection of monocyte-derived primary macrophages by human immunodeficiency virus type 1 and type 2.
Ylisastigui L; Amzazi S; Bakri Y; Vizzavona J; Vita C; Gluckman JC; Benjouad A
Biomed Pharmacother; 1998; 52(10):447-53. PubMed ID: 9921414
[TBL] [Abstract][Full Text] [Related]
33. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.
Simmons G; Clapham PR; Picard L; Offord RE; Rosenkilde MM; Schwartz TW; Buser R; Wells TN; Proudfoot AE
Science; 1997 Apr; 276(5310):276-9. PubMed ID: 9092481
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion.
Gordon CJ; Muesing MA; Proudfoot AE; Power CA; Moore JP; Trkola A
J Virol; 1999 Jan; 73(1):684-94. PubMed ID: 9847374
[TBL] [Abstract][Full Text] [Related]
35. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.
Donzella GA; Schols D; Lin SW; Esté JA; Nagashima KA; Maddon PJ; Allaway GP; Sakmar TP; Henson G; De Clercq E; Moore JP
Nat Med; 1998 Jan; 4(1):72-7. PubMed ID: 9427609
[TBL] [Abstract][Full Text] [Related]
36. Regulation of anti-HIV-1 activity of RANTES by heparan sulfate proteoglycans.
Oravecz T; Pall M; Wang J; Roderiquez G; Ditto M; Norcross MA
J Immunol; 1997 Nov; 159(9):4587-92. PubMed ID: 9379060
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein.
Challita-Eid PM; Klimatcheva E; Day BT; Evans T; Dreyer K; Rimel BJ; Rosenblatt JD; Planelles V
AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1617-24. PubMed ID: 9870314
[TBL] [Abstract][Full Text] [Related]
38. [Cloning and characterization of CCRS receptors of chemokines, principal receptors of the AIDS virus].
Parmentier M
Bull Mem Acad R Med Belg; 1997; 152(7-9):311-6; discussion 317. PubMed ID: 9622941
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.
Dragic T; Litwin V; Allaway GP; Martin SR; Huang Y; Nagashima KA; Cayanan C; Maddon PJ; Koup RA; Moore JP; Paxton WA
Nature; 1996 Jun; 381(6584):667-73. PubMed ID: 8649512
[TBL] [Abstract][Full Text] [Related]
40. Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines.
Hartley O; Dorgham K; Perez-Bercoff D; Cerini F; Heimann A; Gaertner H; Offord RE; Pancino G; Debré P; Gorochov G
J Virol; 2003 Jun; 77(12):6637-44. PubMed ID: 12767983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
